Lacosamide in pediatric and adult patients: Comparison of efficacy and safety

Abstract

Lacosamide may be a useful and safe pharmacological treatment option for both pediatric and adult patients with uncontrolled seizures.

Lacosamide monotherapy in clinical practice: A retrospective chart review

“…Retention rates in the current trial were comparable with those observed in a single‐centre, open‐label study in 58 patients who converted to monotherapy after they had experienced 1‐year seizure freedom with adjunctive lacosamide 10. Moreover, these retention rates are also consistent with the 59.3% retention rate at 1 year described in a study of 59 adults receiving lacosamide in adjunctive use 18. When comparing to Kaplan‐Meier estimates the 1‐year retention rates in our study are higher than those described in another long‐term follow‐up study with lacosamide in adjunctive use (74.5% Kaplan‐Meier estimates) 19.…”

Pharmacological management of epilepsy

“…17 A study comparing efficacy and safety of lacosamide in 118 paediatric and adult patients with uncontrolled epilepsy, showed lacosamide was well tolerated in adults as in previous trials, adverse events occurring at a low frequency, related to the nervous and gastrointestinal systems, included dizziness, headache, nausea, diplopia and somnolence, with dyspepsia onset occurring during the titration period. 18 The discontinuation rate due to side-effects was 8.5%. A 50% seizure reduction was reported in 33-41% of patients receiving lacosamide 200mg-600mg a day.…”

Response of Greater Occipital Nerve Block in Headache Induced by Lacosamide: Report of Case

“…[2] Lakozamid kullanımına bağlı sık görülen yan etkiler arasında baş ağrısı alt sıralarda yer alırken, ilaç bırakma nedenleri arasında ise üst sıralardadır. [3] Biz bu yazıda LCM'e bağlı gelişen baş ağrısında büyük oksipital sinir (GON) blokajının etkili olduğu bir olgu sunduk.…”

“…[3] LCM'in yan etkilerinin değerlendirildiği 11 çalışma-da, yan etkilerin sıklık sırası sersemlik hissi (%57), çift görme (%23), yorgunluk (%18), somnalans (%19) olarak saptanırken, %12 olguda yan etkiler nedeniyle tedaviyi bırakılmıştır (3 baş ağrısı, 2 sersemlik hissi, 2 yorgunluk, 2 dengesizlik). [4,5] Literatürde LCM'e bağlı baş ağrısında, ilaç azaltımı dışında bildirilen bir tedavi seçeneğine rastlanılmamıştır.…”